These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 19584232)

  • 21. Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids.
    Fox BM; Xiao X; Antony S; Kohlhagen G; Pommier Y; Staker BL; Stewart L; Cushman M
    J Med Chem; 2003 Jul; 46(15):3275-82. PubMed ID: 12852757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis of nitrated indenoisoquinolines as topoisomerase I inhibitors.
    Morrell A; Antony S; Kohlhagen G; Pommier Y; Cushman M
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3659-63. PubMed ID: 15203138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.
    Staker BL; Feese MD; Cushman M; Pommier Y; Zembower D; Stewart L; Burgin AB
    J Med Chem; 2005 Apr; 48(7):2336-45. PubMed ID: 15801827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant
    Lee HM; Clark EP; Kuijer MB; Cushman M; Pommier Y; Philpot BD
    Mol Autism; 2018; 9():45. PubMed ID: 30140420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and biological evaluation of bisindenoisoquinolines as topoisomerase I inhibitors.
    Nagarajan M; Morrell A; Antony S; Kohlhagen G; Agama K; Pommier Y; Ragazzon PA; Garbett NC; Chaires JB; Hollingshead M; Cushman M
    J Med Chem; 2006 Aug; 49(17):5129-40. PubMed ID: 16913702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints.
    Pommier Y
    Curr Med Chem Anticancer Agents; 2004 Sep; 4(5):429-34. PubMed ID: 15379698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimization of the indenone ring of indenoisoquinoline topoisomerase I inhibitors.
    Morrell A; Placzek M; Parmley S; Grella B; Antony S; Pommier Y; Cushman M
    J Med Chem; 2007 Sep; 50(18):4388-404. PubMed ID: 17676830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons.
    Strumberg D; Pommier Y; Paull K; Jayaraman M; Nagafuji P; Cushman M
    J Med Chem; 1999 Feb; 42(3):446-57. PubMed ID: 9986716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diversity of DNA topoisomerases I and inhibitors.
    Pommier Y
    Biochimie; 1998 Mar; 80(3):255-70. PubMed ID: 9615865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen.
    Goldwasser F; Bae I; Valenti M; Torres K; Pommier Y
    Cancer Res; 1995 May; 55(10):2116-21. PubMed ID: 7743511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor.
    Morrell A; Antony S; Kohlhagen G; Pommier Y; Cushman M
    J Med Chem; 2006 Dec; 49(26):7740-53. PubMed ID: 17181156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site.
    Urasaki Y; Laco G; Takebayashi Y; Bailly C; Kohlhagen G; Pommier Y
    Cancer Res; 2001 Jan; 61(2):504-8. PubMed ID: 11212241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses.
    Miao ZH; Player A; Shankavaram U; Wang YH; Zimonjic DB; Lorenzi PL; Liao ZY; Liu H; Shimura T; Zhang HL; Meng LH; Zhang YW; Kawasaki ES; Popescu NC; Aladjem MI; Goldstein DJ; Weinstein JN; Pommier Y
    Cancer Res; 2007 Sep; 67(18):8752-61. PubMed ID: 17875716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and anticancer activity of simplified indenoisoquinoline topoisomerase I inhibitors lacking substituents on the aromatic rings.
    Nagarajan M; Morrell A; Fort BC; Meckley MR; Antony S; Kohlhagen G; Pommier Y; Cushman M
    J Med Chem; 2004 Nov; 47(23):5651-61. PubMed ID: 15509164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9.
    Fitzsimmons SA; Workman P; Grever M; Paull K; Camalier R; Lewis AD
    J Natl Cancer Inst; 1996 Mar; 88(5):259-69. PubMed ID: 8614004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison.
    Antony S; Kohlhagen G; Agama K; Jayaraman M; Cao S; Durrani FA; Rustum YM; Cushman M; Pommier Y
    Mol Pharmacol; 2005 Feb; 67(2):523-30. PubMed ID: 15531731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
    Urasaki Y; Laco GS; Pourquier P; Takebayashi Y; Kohlhagen G; Gioffre C; Zhang H; Chatterjee D; Pantazis P; Pommier Y
    Cancer Res; 2001 Mar; 61(5):1964-9. PubMed ID: 11280753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug.
    Li TK; Houghton PJ; Desai SD; Daroui P; Liu AA; Hars ES; Ruchelman AL; LaVoie EJ; Liu LF
    Cancer Res; 2003 Dec; 63(23):8400-7. PubMed ID: 14679002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Silencing and selective methylation of the normal topoisomerase I gene in camptothecin-resistant CEM/C2 human leukemia cells.
    Fujimori A; Hoki Y; Popescu NC; Pommier Y
    Oncol Res; 1996; 8(7-8):295-301. PubMed ID: 8938793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis and biological evaluation of 3-substituted indenoisoquinoline derivatives as topoisomerase I inhibitors.
    Zhao Q; Xu X; Xie Z; Liu X; You Q; Guo Q; Zhong Y; Li Z
    Bioorg Med Chem Lett; 2016 Feb; 26(3):1068-1072. PubMed ID: 26725027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.